Oniosome healthcare pvt. ltd.

What Oniosome healthcare pvt. ltd. does

Oniosome Healthcare Private Limited is an India-based Contract Research Organization (CRO) founded in 2010 and headquartered in Mohali, Punjab, with a manufacturing unit in Ahmedabad, Gujarat (Sanand GIDC). The company provides end-to-end pharmaceutical and biotech R&D services — formulation development, process scale-up, biological process development, analytical testing, regulatory and IP support, and contract manufacturing — to global generic pharmaceutical companies, biotech firms, and academic institutions, with disclosed scale metrics of 1,200+ clients served, 1,500+ projects completed, and 2,000+ students trained.

Its core technical platform is centered on Novel Drug Delivery Systems (NDDS), spanning nanoparticles, liposomal delivery, PEGylation, transdermal systems, dendrimers, SEDDS, and microsphere-based delivery. These capabilities are supported by an in-house analytical instrumentation suite (HPLC, GCMS, LCMS-MS, NMR, SEM, TEM) and GLP-compliant pre-clinical animal study facilities. The company actively develops an internal product pipeline across nanoparticles, liposomes, ophthalmic, oral, and topical dosage forms and pursues technology out-licensing of proprietary formulations to pharma and biotech partners.

Oniosome monetizes through project-based CRO contracts, technology out-licensing of developed formulations, and ancillary services including regulatory filing support, IP prosecution, GMP audit, and professional training. Go-to-market is direct enterprise sales targeting pharma and biotech buyers, with supporting visibility through academic collaborations, a Learning Center, and an "Innovation & Knowledge Ecosystem." Pricing is project-based and not publicly disclosed; the company is privately held and founder-owned, with no public revenue or funding data available.

Name

Oniosome healthcare pvt. ltd.

Legal name

Oniosome Healthcare Private Limited

Website

https://oniosome.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Oniosome Healthcare is an India-based pharmaceutical Contract Research Organization founded in 2010, headquartered in Mohali. It specializes in Novel Drug Delivery Systems — nanoparticles, liposomes, PEGylation — serving global generic pharma companies, biotech firms, and academic institutions with R&D and manufacturing services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Research (CRO)

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215), Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

akta.pro secondary industries

Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)

Keywords

• Pharmaceutical contract research
• Novel drug delivery
• Formulation development
• Analytical testing services
• Biological process development

Headquarters

HQ city

SAS Nagar (Mohali)

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Contract Research & Development Services: CRO services providing pharmaceutical R&D, formulation development, analytical development, and stability studies to pharmaceutical and biotech companies. Revenue generated through project-based contracts and service agreements.
2. Pharmaceutical Process Development & Scale Up: Scale up and technology transfer services for pharmaceutical manufacturing processes, helping clients move from development to commercial production.
3. Biological Process Development: Biologics development services including process optimization, scale-up and tech transfer of mammalian-based processes for monoclonal antibodies and recombinant proteins.
4. Analytical Testing Services: Contract analytical testing and quality control services for pharmaceutical, chemical, and biotechnology companies including method development, validation, and regulatory compliance testing.
5. Regulatory & IP Services: Intellectual property services including patent filing, trademark registration, and regulatory compliance support for pharmaceutical products.
6. Out-licensing & Technology Transfer: Out-licensing agreements for developed formulations and new drug delivery technologies to pharma and biotech companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Oniosome Healthcare is a Contract Research Organization (CRO) providing pharmaceutical and biotechnology R&D services grounded in Novel Drug Delivery Systems (NDDS) expertise. It delivers formulation development, process scale-up, biological process development, analytical testing, regulatory and IP support, and GMP compliance/audit services to global generic pharma companies, biotech firms, and research institutions. It also develops and out-licenses proprietary NDDS-based drug formulations (nanoparticles, liposomes, transdermal, ophthalmic, oral and topical dosage forms) and operates a GLP pre-clinical facility.

Product overview

Oniosome Healthcare Pvt. Ltd. is a Contract Research Organization (CRO) offering integrated pharmaceutical and biotech R&D services rather than a unified software product. The company provides a portfolio of services including Research & Development Services, Pharmaceutical Process Development & Scale Up, Biological Process Development & Scale Up, Analytical Testing Services, and Regulatory & IP Support Services. Their product pipeline includes Nano Particle Products, Liposomes, Ophthalmic Products, and Oral & Topical Dosage Forms, all based on Novel Drug Delivery Systems (NDDS) principles. Supporting services include GMP compliance consulting, audit services, and professional training programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Research & Development Services Comprehensive pharmaceutical R&D services including formulation development, analytical development, and stability studies for pharmaceutical products. Targeted at pharmaceutical and biotech companies requiring outsourced R&D capabilities.
• Pharmaceutical Process Development & Scale Up NDDS-based pharmaceutical product development including nanotechnology, nanoparticles, liposomes, and novel drug delivery systems, with scale-up and technology transfer capabilities. Targeted at pharmaceutical companies moving formulations from lab to commercial production.
• Biological Process Development & Scale Up Biological R&D services covering the entire product lifecycle of drug substances, including process optimization, scale-up, and technology transfer for mammalian-based processes such as monoclonal antibodies and recombinant proteins. Targeted at biotech companies developing biologics and vaccines.
• Analytical Testing Services Comprehensive analytical services including pre-formulation studies, method development and validation, and regulatory compliance testing using chromatography, spectroscopy, and microscopy techniques (HPLC, GC, GCMS, LCMS-MS, NMR, SEM, FESEM, HRTEM, CRYO TEM, XRD, DSC, TGA, particle size and zeta potential). Targeted at pharmaceutical, chemical, and biotechnology companies requiring analytical support and quality control.
• Regulatory & Intellectual Property Rights Support Services IP and regulatory services including patentability assessment, preparation and prosecution of patent applications (India, PCT, and national phase entry in foreign countries), trademark registration, and copyright protection for pharmaceutical innovations. Targeted at pharmaceutical innovators and biotech firms.
• Consultancy & Training Services Quality management services, GMP compliance support, clinical research consultancy, and professional training programs for pharmaceutical industry staff. Targeted at pharma companies seeking compliance and workforce capability support.
• GMP Compliance & Audit Services Third-party audit services, gap assessment, CAPA implementation, and GMP compliance support for pharmaceutical and healthcare sector clients. Targeted at pharmaceutical manufacturers requiring regulatory compliance assurance.
• Pharma & Biotech Research Training Professional training programs for pharmacy and biotechnology students and industry professionals, including lab work, research projects, and coursework support delivered through the Oniosome Learning Centre. Targeted at B.Pharmacy, M.Pharmacy, B.Sc, M.Sc, PhD students and research professionals.

Quantifiable outcome

• 2000+ students trained
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Top Global Generic CompaniescoreStrategic or Co-development PartnerOniosome has built strong alliances and continuing relationships with top global generic companies to offer R&D and formulation development services. The company positions these partnerships as a core part of their business model, providing cost-effective contract research services to major pharmaceutical players seeking to reduce R&D costs and improve profitability.
• Academic InstitutionssupportingStrategic or Co-development PartnerOniosome has collaboration with academia providing access to valuable assets including expert scientists and sophisticated infrastructure. These partnerships support their innovation-driven research approach and provide mutual benefits in research and development activities.
• HospitalssupportingStrategic or Co-development PartnerCollaborations with hospitals provide Oniosome access to clinical expertise and research opportunities. These partnerships complement their drug discovery and development activities.
• Research-based OrganizationssupportingStrategic or Co-development PartnerOniosome has collaboration with other research-based organizations providing access to specialized expertise and infrastructure. These partnerships enable comprehensive R&D capabilities and support their mission to develop innovative healthcare products.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Syngene International: India-based integrated CRO/CDMO offering discovery, development, and manufacturing services to global pharma and biotech. Comparable because it competes head-on with Oniosome for formulation, analytical, and biologics development work from similar global pharma customers.
• Neuland Laboratories: India-based API and formulation CDMO offering drug substance and finished dose development/manufacturing. Comparable as a mid-sized Indian CDMO serving global generic pharma, overlapping Oniosome's generic-pharma-heavy customer book.
• Dishman Carbogen Amcis: India/Switzerland-based CRO/CDMO with API and formulation development services to global pharma. Comparable because it offers integrated small-molecule development and contract manufacturing from India, directly contesting Oniosome's positioning.
• Aragen Life Sciences: Indian CRO/CDMO (formerly GVK Biosciences) providing discovery, process R&D, and formulation development services. Comparable because it serves the same customer base (global generic and innovator pharma) across overlapping formulation and analytical services.
• Sai Life Sciences: India-headquartered CRO/CDMO with discovery, process development, formulation and analytical services for global pharma. Comparable in service mix (small-molecule formulation, analytical testing) and customer overlap with Oniosome.
• Anthem Biosciences: Bengaluru-based CRO/CDMO with formulation development, analytical services, and biologics capabilities. Comparable as a mid-sized Indian CRO competing for similar formulation and analytical outsourcing programs.
• Jubilant Biosys: India-based CRO delivering discovery, development, and analytical services to global pharma and biotech. Comparable in service portfolio (discovery through formulation support) and target customers to Oniosome.

Broad incumbents

• Piramal Pharma Solutions: India-headquartered CDMO offering sterile injectables, oral solid dose, and biologics development/manufacturing at global scale. Comparable because it offers a broader formulation-to-commercial-supply footprint that competes with Oniosome's integrated R&D-to-manufacturing model.
• Eurofins Scientific: Global testing/services group with deep pharmaceutical analytical and formulation-support capabilities across India and globally. Comparable because its pharmaceutical testing arm competes with Oniosome's analytical testing services for many of the same pharma customers.
• Catalent: Global CDMO with specialty drug-delivery capabilities (softgel, Zydis, biologics). Comparable because Catalent's specialty drug-delivery franchise overlaps directly with Oniosome's NDDS (liposomal, transdermal, nanoparticle) development mandate at substantially larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/oniosomehealthcare
• LinkedInlinkedin.com/company/oniosome-healthcare-pvt-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oniosome healthcare pvt. ltd.